TW201023925A - Inhaler - Google Patents

Abstract

An inhaler is disclosed. It comprises a housing to receive an elongate strip of blisters each containing a dose of medicament and being sequentially movable into alignment with means for breaching a blister to enable a user to inhale said dose contained therein. The device comprises a spiral wound element within the housing that receives and coils said strip of blisters that have been breached. The housing includes a compartment to receive used blisters and compartment to receive unused blisters, and a passageway joining the two compartments. Blocking means is provided in the passage to prevent the movement of powdered medicament between the compartments through the passage.

Description

201023925 VI. Description of the Invention: [Technical Field] The present invention relates to an inhalation device for dispersing a powder type medicament in an oral cavity or a nasal cavity, and a 5 inhaler for a strip containing a plurality of sachets, each The sachet has an openable lid and/or base containing a dose of medicament for inhalation by a user of the device. [Prior Art] φ Dispensing a drug in the mouth or nasal cavity using an inhalation device is a very popular application method because it is convenient for the patient to use such a device in public without being noticed. In addition to the distribution of agents for the treatment of respiratory diseases and other local conditions of dyspnea, such devices have recently been used to allow drugs to enter the bloodstream via the lungs, thereby avoiding subcutaneous injections. Pre-packaged dry powder medicaments are very popular, and the common type is a gel pack or a blister pack, each containing the same and single dose of powder that is accurately measured in advance. The sachet is usually made of a malleable foil or Φ plastic material at a low temperature, and includes a puncture or peelable lid. During the manufacturing process, when the medicament is placed in the sachet, High temperature sealing around the sachet. The foil package of each foil package is preferably coated on the outside of the polymer sachet 20 or the gel capsule, so as to be protected from light and ultraviolet rays, and each medicine package can also isolate moisture and gas such as oxygen. Because the drug contacts the above factors, it will adversely affect the function of the inhaler to spread the drug. Therefore, the sachet provides a good preservation environment for each agent. The conventional inhalation device for accommodating the sachet package is, each sachet package 3 25 201023925 5 10 15 20 = several sachets, each containing a pre-measured amount of the drug to be administered, for example, a medicament. After the device is actuated, it will cause the structure to open a sachet by rubbing the 4 teeth or peeling off the lid. Therefore, when the I is carried out, the air will carry the medicine in the sachet through the sachet. With the device, the device enters the lungs through the patient's respiratory tract. The twisted gas or air or other propellant is also used to plow the medicament from the sachet or the mechanism of 'piercing or opening the sachet will also cause the medicament to push out of the pouch and into a storage chamber, then The medicine contained in it will be inhaled immediately. If the inhaler is capable of accommodating a plurality of doses of the medicament, it may be convenient to use the sachet and/or place the sachet every time it is used, so that it can be reused over a period of time. Thus, many conventional devices include a sputum strip for storing a plurality of sachets or a plurality of sachets. Each sachet contains a single dose of medicament. When inhaling a dose of the agent, an indexing mechanism removes the sachet that is emptied from the opening of the mechanical structure, so that the next brand new sachet is moved in and waiting to be opened to release its contents for inhalation. An inhaler of the above type is known from the international patent application filed by the applicant of the present application, the registration number PCT/GB2004/004416, the registration date 2004/10/18, and the claim of the GB patent application (Case No. 0324358.1) 'Registered 曰 2003/10/17' priority. The international patent application is published as WO 2005/037353 A1. According to an embodiment disclosed and described in WO 2005/037353 A1, and FIGS. 1a and 1b, which are shown in the following figures, an inhaler 1 has a housing 2 containing a plurality of sachets 3 therein. a winding strip. 25 201023925 An indexing mechanical structure 4 comprises a single actuating lever 5, each time the actuating lever 5 is rotated in the direction indicated by the arrow A of FIG. 1b, a sachet of the winding strip 3 is unfolded each time, thus the strip The upper sachet will pass through a sachet holder 6 and then through a sachet. Each time the actuating lever 5 is moved 5, when the actuating lever 5 is rotated back (in the direction indicated by the arrow B in FIG. 1b), the piercing member 8 located on the actuating lever 5 itself is pierced by the medicine. The capsule 3a of the capsule puncture point 7, so when the user wants to inhale the medicine through the mouth portion 9, an air flow is generated in the medicine bag 3a, so that the contained medicine escapes the medicine capsule 3a and enters through the mouth portion 9. The user's respiratory tract. Ίο While the inhalation devices described above and in the aforementioned patent applications have many conventional problems associated with such devices, such devices are designed to contain only a small amount of used sachets in the device, so The number of capsules is too large to protrude from the device casing, so the user must separate the used sachets from the unused sachets still in the device and discard the tear-off portions of the sachet strips. . The direction of movement of the used sachet is the direction indicated by arrow C in Figures la and lb. Between each drug, between the capsules or between the plurality of sachets, the sachet strip 3 is perforated or worn to assist in tearing the used sachet from the sachet strip 3. Although the advantage of a device that can spit out a used sachet is particularly light, it is desirable that the entire device can contain all used sachets, so there is no need to separate the used sachets from the device. Pouch. Since the user does not have to pay attention to periodically tearing off and discarding the used sachet strips, this makes the device easier to use, and since the user does not have to touch any used sachets, the fingers can be prevented from being used. The possibility of staining the remaining residue on the sachet. 5 25 201023925 And, this is only the reel that is coiled inside 裴1. However, the used medicine:::: and need to rotate the _ member, to the disk and thus the volume (four) ^ material must be attached to the reel, "patent p can only begin to coil on the reel. The type is winding From the device, and the sac strip has a ring-shaped ring 圏. Figure 2 shows that the device of the central reel rubbing material 'is not required to move the two intermediate mechanical structures 4 and the mechanical structure 4, Responding to the user's heart's 'and the reel's rotation system ^ and the lb's reel's reel move and move' can be referred to the figure structure, if expected. _ turnover for the delicate compartment strip nr long, financial In the __ time, the card is in the sub-, the next door 15 of the smashing piece, and wearing the line in the town will make the strip 14 unable to properly generate the cable threading. · A solid column - the rope because of the ring 81 Set 20, in which part 21, the possibility of paper jam is reduced to the minimum of the subsequent power. As shown in Figure 3a, the path 22, around the number of reels 7 to form the remaining Some of the reels 7 are slid by the main index wheel 4. In the guide wheel 8 of the figure, the splicing of the strip 22 is secondary. ? [Two faces S 'index of the visible mechanical structure 4 and three, to a larger tooth laugh mono - second gear 23 rotates the gear 23 erected on the rear side of the housing 25 of the spool 24 to the center 25 201023925 5 φ 10

20 A potential problem with inhalation devices that retain used sachets is that each capsule will have a small amount of powder remaining after inhalation, at a dose of about 1 /〇 5/〇. In addition, if the patient has not inhaled the medicament in the sac that has been pierced or stripped, the amount of the powder will be indexed first. Therefore, it is important to avoid staining of the unused drug sacs by the escaping powder, as that may have a detrimental effect on the operation of the device, and the sputum can inhale a small amount of residual drug and a sac. The contents of the matter, so that the agent is too embarrassing. Furthermore, if the residual powder is exposed to the air, it will be decomposed and is not suitable for inhalation. SUMMARY OF THE INVENTION In view of the foregoing, the present invention seeks to solve the problem of residual powder contamination' while avoiding other unused sachets in the residual powder staining apparatus' and from being inhaled by the user. According to one aspect of the present invention, an inhaler is provided that includes a housing for receiving a strip containing a plurality of sachets, each pouch containing a dose of a medicament, the outer palate comprising a first containing an unused sachet a compartment, and a second compartment containing the used sachet, the first and second compartments separated by a flexible or movable dividing wall, a member for sequentially moving the medicines The capsule is aligned with a member for opening a sachet to allow a user to inhale the dose, a spiral wound element or a spiral coil former to wind the strip, wherein the inhaler is in the first and the first A channel is included between the two compartments, and a barrier member is located in the channel to prevent the powdered medicament from passing through the channel and the capsule compartment from the second capsule compartment. 25 201023925 Preferably, the spirally wound element is configured such that a plurality of passes: for use in a strip formed by a capsule, can be gradually wound up when the device is used Inside the spiral disk. 5 20 In an embodiment, the helically wound element is rigid. However, in a preferred embodiment, the spiral wound element is formed from a flexible material & The spiral wound element can be formed from a deformable, non-elastic material. However, in a more preferred embodiment, it is formed from a resilient, deformable material. The selection of the elastic force of the spirally wound element is preferably determined by the rigidity of the used portion of the sachet strip, so that the portion of the closed loop of the used portion of the sachet strip will cause any substantial deformation in the spirally wound element. Or expanded, first formed in the spiral coiled component. Alternatively, the structure of the spirally wound element having better elasticity is designed to form a first closed loop when the element begins to flex. In the preferred embodiment, the helically wound element is configured such that the length of the used sachet strip that is crimped therein is increased as more of the sachet is opened, and the helically wound element is radially deployed. Conveniently, the helically wound element has at least one winding over 360. Preferably, at least one of the injuries has a different stiffness in the lengthwise direction of the helically wound element. In particular, the rigidity of the spiral wound element is extinguished toward its internal terminal. One way to reduce the rigidity is to make the thickness of the spiral wound element gradually thin toward its inner terminal end and/or its width is also gradually narrowed toward its internal terminal 201023925. A plurality of holes, slots or slits are formed in the vicinity of the (10) spiral coil element. The /inch spiral wound element is formed of, for example, beryllium bronze, stainless steel, spring steel, shape memory alloy, nylon, PT_elastic material. [_, PTFE or polypropylene spirally wound elements can also be applied to the smoothing-grinding material of the opened bag strip to aid.卞 卷曲 curl, for example, is coated with PTFE to reduce the friction of the surface. The core can be selected. The spirally wound element can be made of a flat strip of a circular, circular or rectangular cross-section material: a material, a jin, or a frictional force can be reduced by at least a wire-wounded helix forming contact area. This is enough to reduce the connection to the strips. These materials and parts can be used to the desired characteristics. It is used in combination to obtain a coil spring formed by the spiral coil element in the preferred embodiment. ', consisting of 4 pieces of material 20 blocking member miscellaneous material splicing-flexible assembly to form the sealed shape of the sachet strip, and wrapped into one of the sachets in the bag strip, i, And the blocking member is provided with the member that opens a sachet. VIII. Alignment of another sachet for use in accordance with the teachings of the present invention provides that the outer casing is adapted to contain a plurality of sachets and the member, and the strips of the crucibles each contain a dose of 9 25 201023925 The medicament, the member is used to open the sachet to sequentially move the sachets to align with an inhalation device, to enable the user to inhale the dose, the two chambers to accommodate Between 'to accommodate unused sachets' and - 挠性 flexibility and domain depletion between the first chamber and the second chamber - to separate the sachet strip from the second, wall, the partition wall includes - Hole, free powder from the used ¥ ^ into the person / f room 'The hole includes the chamber used to avoid the capsule chamber through the (4) hole and into the unused 10 part of the shell, the shape is designed to meet The sac strips are included: the member 'with + to avoid the escape of the powder, and the other - the flexible component 2 forms a seal of the sac strip. The flexible assembly is shaped to conform to the shape of the sachet strip and the flexible member is integrally formed with the dividing wall. A member for avoiding the escape of the powder is arranged to align one of the bladders of the bag strip, wherein the other bladder is aligned with the member 0 20 for opening a sachet, although the unused sachet is used. The straps and the opened sachets can each be located in different chambers. In one embodiment, the housing includes a common compartment to accommodate both unused portions of the sachet strip and used portions. . This has the advantage that the compartment is configured such that as the size of the used portion of the strip increases, a portion of the strip that has been used in the strip will occupy an area of the chamber. The area is initially occupied by unused portions of the sachet strip. In an embodiment, the dividing wall may be rigid, but configured to slide within the outer casing 25 201023925, such that the relative size of the unused sachet chamber and the used capsule chamber can be varied. One or both ends of the flexible dividing wall can be secured to the peripheral and include a foam strip that includes a stiffening element. In one embodiment, the flexible dividing wall is movable and has one end secured to the outer casing so that it can be pivoted about the end within the outer casing. 10

20 25 In an embodiment, the flexible and/or movable dividing wall is flexible and configured to extend across the space between the side walls of the inhaler to avoid powder in the The used capsule chamber is traversed between the used capsule chamber. In one embodiment, the flexible dividing wall is at least partially attached to the spiral wound element. The flexible dividing wall can also be designed to apply a binding force or to force one or both of the capsule loops. This binding force can be generated, for example, by the rigidity of the partition wall or by the frictional force generated when the partition wall slides relative to the wall of the outer casing chamber. It is particularly helpful if the material of the spirally wound element of the used portion of the capsule ring is selected to be extremely elastic' and ensures that the loop of the used sachet is as small as possible. In one embodiment, the inhaler comprises a second helically wound element in which an 'unused sachet strip can be wound inside the outer casing, such that when the first helical coiled element expands, the second helical coil The component shrinks because when the size of the loop formed by the used portion of the strip is increased, the size of the loop formed by the unused portion of the strip is reduced. The flexible partition can be fixed to the outer shell at each end. . 11 201023925 and crossed the inhaler's 'and its configuration to extend the unused drug sputum: space to avoid the powder in the unused sac chamber and the width of the flexible compartment of the sac chamber (4) is greater than the side wall surface 2 Therefore, the two rooms are crossed between the areas. The edge of the side wall surface of B and the flexible partition wall of the compartment preferably comprise a blister strip. In the embodiment, the suction station 15 20 ❹ is reduced. The unused portion is formed. The ring size is excellent, the spiral coiled component is equipped with ❹ =::: in the strip is not due to the spiral disk == = disk (Li. _). Unrolled or partially unwound the hair. δ3 ,,.. Π5 ” arbitrary, and σ. For example, the spirally wound element can be used in conjunction with a device for squeezing a used sachet, and the inhaler of the present invention can be either passive or primary in a passive device. The medicament flows out in response to the user inhaling through the mouthpiece 12 25 201023925. However, in an active device, the inhaler includes means for generating a pressurized flow of gas through the sachet to carry the drug and carry it away from the sachet through the mouthpiece into the respiratory tract of the user. In one embodiment, the inhaler is provided with a source of compressed gas or air 5 within the housing. [Embodiment] Hereinafter, an embodiment of the present invention will be described by way of example only with reference to the following FIGS. 4 to 20. Ίο Regarding the "unused" and "used" sachets mentioned in this article, we should understand that the "unused" sachet represents the drug that has not been passed through the sachet and is contained in it. Complete sachet. The "used" sachet represents a sachet that has passed through the capsule through a response to the user's movement of the actuator, and can be released for use because it is worn. Although in general, a "used" sachet represents a sachet to which the contained medicament has been inhaled, it should also include a pill that has been puncture through the puncture, but still contains some or all of the medicament. bag. For example, this may occur when the user pulls the actuator to move the sachet strip without inhaling the medicament from the sachet that was previously puncture open. 20 shows a conventional inhalation device in which an elastically movable partition wall 90 extends toward a spirally wound element 60 and the used portion 61 of the sachet strip is used and the unused portion 61a is separated from each other. The partition wall 90 is fixed to the inner wall of the device with its respective ends 90a, 90b. 5 is a partial cross-sectional view showing that the partition wall 90 is flexible and elastic at a width of 25" across the width thereof, and is wider than the two faces of the outer casing 2. 13 201023925 between the side wall faces 2a and 2b The distance "z" is such that the partition wall 9 is slightly deformed and is compressed in the width direction to be held between the side wall faces 2a and 2b of the outer casing, so that the edge of the partition wall 9〇 is shown in Fig. The direction of the F is applied to apply pressure to the side wall faces 2a, 2b. Although the pressure exerted by the dividing wall 5 on the side wall faces 2a, 2b must be such as to prevent the powder from entering the unused capsule chamber from the used capsule chamber, It is also important to ensure that the pressure is not too large and that the friction between the partition wall 90 and the side wall faces 2a, 2b is sufficiently large, otherwise the used sachet strip 61 or the spiral wound element 60 expands and pushes toward the partition wall 9. When 〇, the partition wall 9 ruptures 10 or does not move smoothly. Figures 6a to 6d show that during use of the device 7 以及, and when the unused portion 61a of the sac strip is unfolded and in the sac strip The used part 61 is rolled up in the spiral wound element 6〇 or included in the used In the case of the capsule, the elastic partition wall 90 is moved or elastically deformed due to the expansion of the used sachet strip or the spiral coil element 15 6〇. The flexible partition 90 is made of a flexible one. The blister strip (f〇am sMp) is formed to be sized to be slightly squeezed between the uranium wall surface and the rear wall surface of the outer shell, so that even when the blister strip is expanded by 20 The powder seal can be effectively maintained while moving under the pressure generated by the element 6. The blister strip is known to have a good balance between elasticity and low friction resistance. The material of the blister strip can be Eva, PVA, PU. As well as polywei oxygen, many other suitable materials may be used. Depending on the rigidity of the blister strip, a stiffer belt (not shown) which is narrower than the blister strip may be fixed to the blister strip to increase its rigidity. Or 'the strip formed by the joined just-in-time 201023925 segment can be fixed to the elastic sealing strip r to control its movement. In other embodiments without the drawings, the partition wall $$ can itself be rigid by a long column Fragments that are linked and pivoted to each other^ Alternatively, a resilient partition wall 91 or portions thereof can be partially secured to the outer surface of the spiral wound element 60, as shown in Figure 7. Also seen in the embodiment of Figure 6, the partition wall At least one end 9la, ^ can be fixed to the wall surface of the device.

20 However, as can be seen in Figures 4 and 7, only the elastic dividing wall separates the used and unused areas of the outer casing, leaving space in the passage of the sachet strip two adjacent to the two chambers. . The passage is defined by the outer casing B and a vertical rib 7a, and is shown in Fig. 4 and Fig. 4 as "P", wherein the first end rib 71a of the elastic wall 90. Therefore, 'only the effective sealing effect of the elastic wall 9 〇 on both sides of the outer casing 7 ι, the elastic side of the outer casing may still be contaminated by the residual powder (ie via the above-mentioned passage through the connecting casing and unused) ). Thus, FIG. 8 illustrates an embodiment of the present invention comprising a suction device having a housing 271 and an elastically movable partition wall, the pair of helically coiled elements 26() extending and being in the bag strip = The part 261 is separated from the unused part by 2 cents. The set 270 includes an indexing mechanism 274 that includes an actuator π = each time the actuator 275 is rotated as described above, the capsule is stretched from the loop each time, so that the strip of the capsule passes through the holder And then through the - drug capsule through the 277. When the user performs 15 25 201023925 = gas through a mouthful of milk, an air flow is generated in the sachet to allow the contained medicament to escape from the capsule, and the mouth 279 enters the user's respiratory tract. The blade partition 29 is fixed to the top surface of the device with its ends 290a, 290b. As in the embodiment shown in FIG. 4, the partition wall 29 is flexible and elastic across the width thereof, and is wider than the outer casing. Between the face-to-face side walls, the partition wall 29 is slightly deformed as described above and is compressed and held between the side wall faces. The first end 290a of the elastic partition wall 290 is fixed to a rib 291 formed in the outer casing 271 and extends between the side walls of the outer casing 271. Thereby, the side wall surface of the outer casing 271 and the edge wall (located on the left side of FIG. 22) and the rib 291 together define a passage 292 through which the used portion 261 of the sac strip begins to pass from the passage 292. The unused capsule chamber enters the used capsule chamber. Thus, it will be appreciated that channel 292 is the only possible passage of residual powder from the used capsule chamber in the housing into the unused capsule chamber. Thus, the embodiment of the invention illustrated in Figure 8 would be different from the conventional device of Figure 4 in that the embodiment of Figure 8 includes a member that traverses the passageway to substantially close the passageway near the sachet passage to a minimum of either The possibility of residual powder from the used capsule chamber in the outer casing to the unused capsule chamber is substantially reduced. A variety of configurations of such components are contemplated within the scope of the invention, some of which are described below. 8 and 9 show that the passage 292 of the outer casing 271 is provided with a first member 293 which protrudes from the rib 291 toward the outer wall surface of the outer casing 271, and a second member 294 which is located on the outer wall surface of the outer casing 271 facing The first element 293 protrudes therefrom. The first member 293 includes an arch 25 201023925 and can be integrally formed with the rib 291 or a separate component on the 291. The first and second members are torn apart, so that the hole 296 between the two is formed to have a rectangular slit 296a or a flat edge against the slit long edge 2% a tr portion 296b. The resulting aperture 296 is thus shaped such that the sachet 1 (10) is able to pass through the aperture 296' where the flat portion of the sachet strip is located within the slit 296a and the sachet is positioned within the segmented portion.胄9 Zoom ❹ 10 15 20 = Sectional view is more clearly 2% of the size of the hole is designed to be slightly larger than the size of the corresponding sac strip, so the sac strip and the eight sac can pass through the hole 296 produces a tight gap. Thereby, the powder entering the unused capsule chamber from the used capsule chamber is minimized or substantially avoided. It will be appreciated that when the user operates the actuator 275, the indexer mechanical structure 274 of the inhaler only causes the strip of the capsule to move and because of the π strip, the strip will be in phase with the inhaler. The position, and then also - remains in the same position until the actuator 2^75 is operated again. Furthermore, the gauge spacing of the sachets in the sachet strip enables the strips of the sachet to be sequentially moved each time the actuator 275 is operated, so that the sub-drug along the strip of the sachet is positioned at The former - the same as the sachet: set. Therefore, the second and second members 293, 294 are disposed in the outer casing π, so that the sachet in the sachet strip is located in the hole 296 at the puncture/intake/storage position of the sachet strip, so The actuator 275 is briefly indexed to index the strip of the sachet, otherwise the aperture 296 will remain in close engagement with the surrounding capsule and the sachet strip. Another variant of the embodiment illustrated in Figures 8 and 9 is shown in Figures 17 25 201023925 and Figure 11. Similar components will use the same reference number and will not be repeated. The embodiment of Figures 10 and 11 differs from Figures 8 and 9 in that the first member 293' is made of a flexible material, such as a bubble or rubber, and is fixed to the rib 29 The vacancy 295' and the second element 293' are sized such that the size of the aperture 296 is the same as or slightly smaller than the cross-sectional size of the sachet strip and the sachet, so that the flexible material can form a contact fit therewith and only slightly Deformation to achieve an effective seal between used and unused pod chambers. 10 15 20 25 Referring to the embodiment shown in Figures 10 and 11, it can be seen that another configuration of the flexible first jaws 293", 293"" can also be included in the scope of the present invention and also In Figures 12A through 12C, Figure 12A shows a first option in which there is no recessed portion 295, and instead its end is flat. In this embodiment, when the sachet strip is indexed The flexible component 293" is biased only around the shape of the sachet. Figure 12B shows a second option 293,, which does not contain the vacant portion 295, but instead is more like the flexible element 293 of the closed 12A, and has a straight, rigid end. The end has a sturdy, 293", multiple incisions 295, '俾 formation - comb or brush "is the young chick / micro-junction" _" eye capsule strips then produce the necessary deformation ' Thereby reducing the resistance of the sachet strip as it moves 'below the hard flat end = in Figure 12A while still maintaining a seal against the sachet. Figure 12C shows the first-aged element 293 of Figure 1()/embodiment, with a vacancy, 1. In all of the embodiments in FIGS. 8 to 12C, the 293, 293", 293" can be formed as a portion L of the ribs or

18 201023925 #二在支柱杆291的分离组件. However, it is conceivable that a 7L piece can also be formed as a part of the partition wall 29〇. Such an embodiment is illustrated in Figures 13 and 14. Again, similar trees will retain the same reference number of 5 and will not repeat their narrative. The flexible partition wall 290 passes over the top end of the rib 291 and its end portion 29a extends toward the second member 294. The end 29〇a of the partition wall 290 is spaced apart from the second element and has an arcuate vacancy, as shown in the figure and FIG. U, and can also perform the above. The same function of the embodiment. In addition, the end 2 of the partition wall 29G can also be shaped as a flat end 290a, or a comb/brush-like end 290a", as described above with respect to Figures 12A and 12B. Figures HA and 15B These choices are apparent and have the same utility and advantages as described above. Figure 15C shows the end 29〇a of the dividing wall of Figures 13 and 14. 15 - Figures 13 to 15C show and describe all embodiments including the second The f piece 294, which is a separate member of the partition wall 290, is formed integrally with or fixed to the wall surface of the outer casing 271. However, Figs. 16 and 17 show another embodiment in which the separation is not provided. In contrast, the partition wall 290 extends over the top end of the rib 291 and the second end portion 290a until it touches the wall surface of the outer casing 271, for example, adhered thereto. The used chamber enters the unused chamber via the passage 292, and a hole 297 is formed in the partition wall 290 between the rib 291 and the wall surface of the outer casing 271, and the hole 297 is shaped to have a segmented portion 297b. The gap 297a, commensurate with the one in Figure 25-17 The sac strip and the sachet. As described above, the size of the hole 297 is set to be the same as or slightly smaller than the size of the sachet strip and the sachet, so that the 201023925 flexible material can form a contact fit with it and only Slightly deformed, an effective fit is achieved between the used and unused sachet chambers. The partition wall includes a slit 298 extending from the aperture 297 to the edge of the partition wall 290. This enables the sachet strip to be loaded into the inhalation In the device 27, and by sliding the sachet 5 strip over the slit 298 positioned on the partition wall 290, = the distal end of the sachet strip need not be fed into the hole 297. In the embodiment, the inhaler is arranged as shown in Figs. 16 and 17, except that the end point 290a of the partition wall is not fixed to the face wall of the outer casing 271' and does not have a hole 10 297 thereon. The distal end of the partition 290 includes an arcuate vacancy and is configured to bias away from the wall of the outer casing 271 away from the rib 291. In use, the end of the dividing wall biases the sac strip against the outer casing 271. The wall's and its arched vacancies surround the sachet and are used and not The passage between the used capsule chambers forms a seal. Also, the end of the partition wall may have a flat end or a comb/brush structure as in the other embodiments described above, without an arched portion. It should be understood that the above embodiment including the second member 294 can be fixed to the wall surface of the outer casing 271 with a flexible material to achieve a conforming fit with the sachet strip, or can be formed with the outer casing 271. A solid element that is integral or affixed thereto. In any embodiment utilizing a helically wound element of the type described above, the stiffness of the helically wound element may be constant along its length. However, it is also helpful if the rigidity of the spirally wound element is locally lowered toward its inner terminal 60a, since this helps the shape of the spirally wound element to be smoother at the extension 25 and avoids the end of the spirally wound element "scratching 201023925" (clawing) the surface of the sac strip. The rigidity can be easily changed by changing the thickness and width of the spirally wound element or by shaping it to be tapered toward its inner end 6〇a. A portion of the length of the spirally wound element may be tapered toward the inner end. Reducing 50% of the cross-sectional area at the last 5 20 mm of the spiral length works well. The spiral wound element can also be provided with a series of holes or slits to reduce its rigidity. Many of the medicaments can be administered by using the inhaler of the present invention alone. Such agents include those suitable for the treatment of asthma, chronic lung disease (COPD), respiratory infections, rhinitis, allergic rhinitis, nasal disorders and ίο disorders; common and specific symptoms, and systemic diseases transmitted by the lungs or nasal passages. Such agents include, but are not limited to, β2_agonists such as carmoterol, fenoterol, formoterol, levafloxacin (evaibuterol), 咄布特罗(pirbuterol), reproter〇i, metaproterenol, Hmiterol, salmeterol, indacaterol, special Terbutaline, orciprenaiine, clenbuterol, bambuterol, procaterol, broxaterol, pyridoxol 2〇 (Picumeterol), and bitolterol; non-selective β-stimulant, such as ephedrine, isoproterenol; phosphodiesterase (PDE) inhibitors, such as guanidine Astragalus, theophylline, amine theophylline, choline theophylline, and selective PDE isozyme inhibitors. PDE 3 inhibitors, such as miirinone and motapizone; PDE 4 inhibition Agents such as rolipram 201023925 (rolipram), cilostatin ( Ci〇milast), roflumilast, oglemilast, and 〇N〇6126; PDE 3/4 inhibitors such as zardaverine and tolafentrine Inducer of HDAC2, such as theophylline; anticholinergic 5, including muscarinic receptor (Ml, M2 and M3) antagonists, such as atropine, acrosine, and gansu (glycopyrrolate), ipratropium, tiotropium, oxitropium, NVA237, pirenzepine' and telenzepine; giant cell οοο (mast) Cell stabilizer), such as cromoglycate and ketotifen; bronchial anti-inflammatory drugs, such as nedocromil; steroids such as beclometasone, dexamethasone , fluticasone, budesonide, flunisolide, rofleponide, triamcinolone, butixocort, mometasone (mometasone), and the ring (ciclesonide); disease-modifying drugs, such as methotrexate, leflunomide, teriflunomide, and hydroxychloropurine; histamine type 1 receptor orange anti-caries, such as cetamine 11 (cetirizine), loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, aspirin Astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, and 0斯 斯 25 201023925 (mizolastine); antibacterial agent and cystic fibrosis medication and / or tuberculosis treatment drugs, such as Pssudomonas aeruginosa infection vaccine (such as Aerougen®), mannitol, denufosol (denufosol) ), glutathione, N-acetoxycysteine, amikacin, duramycin, gentamycin, tobramycin, arva Chain enzyme (dornase alfa), avar-1 anti-pancreatic egg Enzymes, heparin, dextran, capreomyci, vancomycin, meropenem, ciprofloxacin, piperacillin, and rifamycin ( Rifampicin); a phlegm drug for the treatment of COPD and cystic fibrosis, such as (N-acetylcysteinia) and amine (ambroxol); histamine type 2 receptor antagonist; tachykinin Antagonist (tachykinin neurokinin antagonist); triptans such as almotriptan, rizatriptan, naratriptan, zolmitriptan , sumatriptan, eletriptan, and frovatriptan; neuromedicines such as apomorphine, dronabinol, dihydroergotamine (dihydroergotamine), and loxapine; anti-disease 2 anti-drugs such as foscarnet, acyclovir, famciclovir, valacyclovir, more Ganciclovir, cidofovir (cido Fovir); amantadine, rimantadine; ribavirin; zanamivir and oseltamavir and placonaril, Protease inhibitor 23 201023925 (eg ruprintrivir, indinavir, nelfinavir, ritonavir and saquinavir), nucleosides Reverse transcriptase inhibitors (eg, didanosine, lamivudine, stavudine, zalcitabine, and zidovudine), And non-nucleoside reverse transcriptase inhibitors (such as nevirapine and efavirenz); α-1/α-2 receptor agonists, such as propylhexedrine, phenylephrine ), phenylpropanolamine, ephedra, pseudoephedrine, naphazoline, 曱 ° sitting (0\又^^32〇1^^), tetrahydrogen Oxazolinium 6 beats & 1^(11*02〇1^^), xylometazoline, tramazoline, And ethyl norepinephrine; anticoagulant/anti-inflammatory agents, such as bemiparin, enoxaparin, heparin; anti-infective agents, 15 such as cephalosporin, penicillin, tetracycline , macrolide, β-indoleamine, flouroquinolones, streptomycin, decylamine, aminoglycoside (eg, reflux), doripenem, Pentamidine, c〇iistimethate, and aztreonam; agents for sexual health, sexual dysfunction (including premature ejaculation), 20 such as apomorphine, VR776, via the brain 5 serotonin (5HT) or norepinephrine-mediated pathway agents, leuprolide' and PDE 5 inhibitors such as sildenafil, tadalafil (tadalafll) and vastatitis Vardenafil, a leucovorin regulator such as ziieut〇n, fenleut〇n, tepoxalin, montelukast 201023925 (montelukast), Zafiriukast, ontazolast, abiukast, Pranlikast, veriukast, and ilarukast; including 5 agents that induce one of the nitric oxide synthase (iN0S) inhibition, anti-genuines such as amphotericin B, natamycin, and nystatin; analgesics such as codeine, dihydromorphine, ergotamine, fentanyl, cannabinoids, and Non-anxiety/anti-depressant drugs, such as benzodiazepines and benz diazepines, diazepam, midazolam, Chlordiazepoxide, lorazepam, oxazepam, clobazam, alprazolam, clonazepam, flurazepam (flurazepam), salazepam (zolazepam); trypsin and elastase inhibitor; β-2 integrase 15 ubiquitin inhibitor, glandular agonist or antagonist, such as glandular 2α agonist; Blockers such as gallapamil and diltiazem; forefront Analogs, such as iloprost; endothelin receptor antagonists, such as LU-135252; cytokine antagonists such as chemoattractant antagonists and inhibitors of cytokines and 2-oxime modulators, including pro-inflammatory Regulators and inhibitors of transcription factors, NFkB; interleukin and interleukin inhibitors, such as aldesleukin; therapeutic proteins and peptides, such as insulin, nore and insulin (insulin aspart) ), insulin glulisine; insulin lispro, neutral soluble solubilin, isophane insulin, insulin 25 25 201023925 zinc (insulin zinc), refined zinc Protamine zinc insulin, insulin analogues, acylated insulin, insulin glargine, insulin detemir, glycoside, glucagon-like peptides, Exendin; enzymes, such as the avalanche chain enzyme; systemic active macromolecules such as human growth hormone, leuprolide, alpha-interferon, growth hormone (eg , insulin-like growth factor type 1, hormones such as epinephrine, testosterone, and parathyroid hormone and its analogs (eg ' Ostabolin-C); osteoporosis drugs, such as bis-acid Salt, anticancer drugs such as anthracyclines, doxorubicin, idambicin, epirubicin, amidoxime, taxane, paclitaxel , docetaxel, cisplatin, vinblastine, vincristine and 5-fluorouridine; anticoagulants such as blood factors and blood factor constructs (bi〇〇d Factor construct), such as FVIII-Fc and ΠΧ-Fc; for example, FVll-Fc; immunomodulators such as cyclosporine, sir〇Hmus, and tacrolimus; anti-hyperplasia Immunosuppressive agents, such as azathioprine and myC〇phen〇iate mofetil; cytokines (eg, interferon, interferon (3, interleukin, and interleukin antagonist) And inhibitor) Acids; vaccines, such as influenza vaccines, anti-obesity drugs; diagnostic drugs and gene therapies. It will be well known to those skilled in the art that, where applicable, the agent should be linked to one or more carrier molecules and or in the form of a conventional drug, salt, ester or solvate to render the drug active and /201023925 or stable. Sexuality is at its best. 10 15 10 20 An inhaler according to the invention may also be used to administer a combined preparation of at least two different drugs. A particular combination formulation of the two drugs mentioned above includes a combination of a steroid and a beta 2 agonist. Examples of such combinations are B. miso and Formoterol; beclomethasone and salmeterol; fluticasone and formoterol; fluticasone and salmeterol; budesonide and formoterol; budesonide and sami Troy; flunisolide and formoterol; flunisolide and shamotrol; ciclesonide and salmeterol; ciclesonide and formoterol; mometasone and salmeterol ; and mometasone and formoterol. In particular, the inhaler according to the invention can also be used to administer a combination of three different drugs. It will be well understood by those skilled in the art that, where applicable, the agent should be linked to one or more carrier molecules and/or to a pre-drug, salt, ester or solvent form for activity and/or stability of the drug. At best. It is also possible that the pharmaceutical composition comprises at least one (preferably one) anticholinergic agent 1 and optionally in combination with a pharmaceutically acceptable excipient. Anticholinergic agent 1 can be selected from the group consisting of: a) tiiotropium salts la, b) compounds of formula lc

201023925

A represents a double bond base, which is selected and hV丨

C-G Η ;

X 15 20 generation = anion with a valence negative, preferably selected from the anion: gas ion, gas ion, sulfate ion in the ion, heterogen ion, strontium dibutylate ion, acid chloride ion, Citrate::, sulphate away? , tartarate ion, oxalate ion, glass acid, ion, benzoate ion and p-toluene ion. ...may be the same or different, representing a group selected from the group consisting of methyl, ethyl, n-yl and isopropyl' which may be optionally substituted by hydroxy or fluoro, preferably unsubstituted M, R, R, R and R may be the same or different and represent hydrogen, methyl, ethyl, decyloxy, ethoxy, hydroxy, fluoro, chloro, bromo, CN, cf3, or no2; R7 represents hydrogen, methyl, ethyl, methoxy, ethoxy, -CH2-F, -CH2-CH2-F '-0-CH2-F > -O-CH2-CH2-F '-CH2- OH ' -CH2-CH2-OH, CF3, -CH2-OMe, -CH2-CH2-OMe, -CH2-OEt, -CH2-CH2-OEt, -O-COMe, -O-COEt, -Q-COCF3, -Q-COCF3, fluorine, gas or bromine; c) compound of formula Id ❹ 28 201023925

A, X, r1 and R2 may have the aforementioned meanings, and wherein r7, r8,

R9, R1. , R11 and R12 may be the same or different and represent hydrogen, methyl, ethyl, decyloxy, ethoxy, trans-base, gas, chlorine, bromine, CN, CF3, or N02, and the premise is r7, At least one of r8, r9, R10, Ru and R12 is a non-hydrogen, d) compound of formula le

10: and X may have the aforementioned meanings, and wherein f group, f group, ethyl group, cleavage, chf2 or fluorine; the same or different 疋, representing C]_C5-alkyl, can be a good disk 1 ^, Sexually substituted by C3'C6_ ring, recorded or substituted, or two-represented W-ene bridge; R, R, R]3, 盥14, c may be the same or different, representing hydrogen, 29 15 1 C4 alkyl, -Cl_c4-decyloxy, thiol, -CF3, -CHF2, 201023925 CN-, N〇2, or halogen, e) compound of the formula If

Wherein X' may have the aforementioned meaning, and wherein 5 D and B may be the same or different, preferably the same, representing -0, -S, -NH, -CH2, -CHNCH, or -NCCrQ-alkyl )-; R16 represents nitrogen, light base, -C1-4C-alkyl, -C1-C4-indolyl, -C1-C4-fine'yl-halogen, -〇_Ci-C4_thinyl, _0_C0Ci-C4_Hyun, -O-COCrCV alkenyl-halogen, -CrCV alkenyl-C3-C6-cycloalkane,-0-C0CF3, or halogen; R1" and R2" may be the same or different , representing a Q-C5-alkyl group, optionally substituted by c3-c6-cycloalkyl, hydroxy or i-, or R1'' together with R2' represents a -C3-C5-ene bridge; R17, R18, R17' and R18' may be the same or different and represent hydrogen, 15-CVC4-alkyl, -CrCr alkoxy, hydroxy, -CF3, -CHF2, CN, N02, or halogen;

Rx and Rx' may be the same or different and represent hydrogen, -CVCr alkyl, -CkQ-alkoxy, hydroxy, -CF3, -CHF2, CN, N02, or halogen, or

Rx together with Rx' represents a single bond or a bridging group selected from a bridging group: -0, -S, 30 20 201023925 -NH, -CH2, -CH2-CH2·, -NCCVCV alkyl), -CHCCrQ- Base)-' and -C(Ci_C4 alkyl) 2 ' and f) compound of formula lg

^ X

\ / A- represents a double bond selected from the following: and Η 〇 Η; R19 represents hydroxy, thiol, hydroxymethyl, ethyl, -CF3, CHF2, or fluorine;

15 R1 〃' and R2'〃 may be the same or different and represent Cl_C5_alkyl, which can be optionally substituted with c3-c6-cycloalkyl, hydroxy or halogen, or R1'" and R2" Representing -C3-C5-alkenyl-bridge; R2G, R21, R20' and R21' may be the same or different and represent hydrogen, -C1-C4-Hyun", -C1-C4-decyloxy, Base group, -CF3, -CHF. , CN, N〇2, or halogen. Compounds of the formula lc are known in the art (WO 02/32899). In a preferred embodiment of the invention, the process comprises: 31 201023925 A compound of the formula lc, wherein X represents a desert; Ethyl when 5 R3mR6:_w is different, represents gas, methyl 7 methoxy, hydrazine or fluorine; 2hydromethyl or fluoro' is optionally used together with a pharmaceutically acceptable excipient. A represents the slave

The compound of the formula lc is specifically a double bond group:

The compound of the formula lc can be selectively administered in the form of an individual optical isomer, a mixture of individual mirror image isomers, or a racemate thereof. Of particular importance within the process according to the invention are the following compounds of the formula lc: tropenol 2,2-diphenylpropionate oxime bromide, scopolamine 2,2-di Phenylpropionate oxime bromide, 20

Terpene alcohol 2-fluoro-2,2-diphenylacetate oxime bromide, and the formula alcohol 2-gas-2,2-diphenylacetic acid acetate bromide. Compounds of formula Id are well known in the art (WO 02/32898). In a preferred embodiment of the invention, the method comprises: 32 201023925 applying a compound of formula id, wherein

10' represents that the double bond group KVR and R2 selected from the following may be the same or different, and the group selected from -, preferably A = · represents from methyl and ethyl when R7, ~, "represents hydrogen" , fluorine, gas or performance, compared with: = phase _ or different, R8, R9, R1, R11 and R! C'j are given as /,, optionally with the medicinal medicinal agent; The base of the lacquer of the milk base's correcting the size of the material is ^ 15

托品,3,3,,4,4,-tetraoxydiphenylglycolic acid vinegar, desert, 3,3,,4,4,-tetrafluorodiphenylglycolic acid vinegar Sterol 3,3,,4,4'-difluorodiphenylglycolate oxime bromide, tropinol 4,4,-difluorodiphenyl glycolate methyl bromide, Dongliang saponin 3,3' - Difluorodiphenylglycolate desertification, and tropinol 3,3'-difluorodiphenyl glycolate methyl bromide. The pharmaceutical composition according to the present invention may contain a compound of the formula Id, optionally in the form of a mixture of individual optical isomers, individual mirror image isomers, or a racemate thereof. 20 Compounds of formula le are well known in the art (w〇 03/064419). In a preferred embodiment of the invention, the method comprises: applying a compound of the formula le, wherein A represents a double bond selected from the group consisting of: poor and 1·^^; 33 201023925 χ· represents an anion, preferably Selected from the following: gas, bromine and sulfonate, preferably bromine; R15 represents hydroxy, decyl or fluoro, preferably methyl or hydroxy; R1' and R2' may be the same or different, representing Methyl or ethyl, more preferably methyl; 1113, ruler 14, 1113' and ruler 14' may be the same or different and represent hydrogen, -CF3, -CHF2, or fluorine, preferably hydrogen or Fluorine is optionally used with pharmaceutically acceptable excipients. In a preferred embodiment of the invention, the method comprises: ίο administering a compound of formula le, wherein

A is a double bond group selected from the group consisting of: S—S and; π represents bromine; R15 represents a hydrogen group or a fluorenyl group, preferably a methyl group; and R1′ and R2′ may be the same or different and represent a fluorenyl group. Or an ethyl group, preferably an anthracenyl group; R13, R14, R13' and R14' may be the same or different and represent hydrogen or fluorine, optionally together with a pharmaceutically acceptable excipient. Of particular importance within the process according to the invention are the following compounds of the formula: 2 terpineol 9-hydroxy-hydrazone-9-carboxylate oxime bromide; tropinol 9-gas-苐-9- Carboxylic acid ester 曱 bromide; East sterol 9-hydroxy-hydrazine-9-carboxylate 曱 bromide; East sterol 9-fluoro-fluorene-9-carboxylate 曱 bromide; tropinol 9-fluorenyl -苐-9·carboxylate 曱 bromide; 201023925 East sterol 9-methyl-hydrazine-9-decanoate methyl bromide. The pharmaceutical composition according to the present invention may contain a compound of the formula le, optionally administered as an individual optical isomer, a mixture of individual mirror image isomers, or a racemate thereof. Compounds of formula If are known in the art (WO 03/064418). In another preferred embodiment of the invention, the method comprises:

15 ❹ 20 A compound of the formula If, which represents chlorine, bromine or methyl ketone, preferably bromine; D and B may be the same or different, preferably the same 'representative _ 〇, -S, - NH, or -CH=CH-; R16 represents hydrogen, hydroxy, -Crc4-alkyl, -CVCV alkoxy, -CF3, -CHF2, fluorine, chlorine, or bromine; R and R may be the same or different 'Represents a C1-C4-alkyl group, which may be optionally substituted with: hydroxy, fluoro, chloro or bromo, or R1'' and R2 together represent a -^^-thin bridge; R17, R18, R17 and Rls' may Is the same or different represents hydrogen, _crc4-alkyl, _Ci_C4_ alkoxy, hydroxy, _Cf3, _CHF2, CN^N02, fluorine, chlorine, or bromine;

Rx and Rx may be the same or different and represent hydrogen, _Ci_C4_alkyl, -Cl_C4_alkoxy, hydroxy, -CF3, -CHF2, CN, N02, fluorine, gas' or bromine, or

Rx and Rx - represent a single bond or a bridging group selected from the group consisting of: _ 〇, _s, -NH, and -CHy, optionally used with pharmaceutically acceptable excipients 25 201023925. In still another preferred embodiment of the present invention, the method comprises: administering a compound of the formula if x_ represents chlorine, bromine, or sulfonate, preferably bromine;

5 D and B may be the same or different, preferably the same, representing -S or -CH=CH-; R16 represents a hydrogen group, a hydroxyl group, or a methyl group; R1" and R2" may be the same or different , represents methyl or ethyl; R17, R18, R17' and R18' may be the same or different and represent hydrogen, ίο-CF3, or fluorine, preferably hydrogen;

Rx and Rx' may be the same or different and represent a hydrogen group, -CF3, or fluorine, preferably hydrogen, or

Rx together with Rx' represents a single bond or a bridging group-0-, optionally used with pharmaceutically acceptable excipients. In a further preferred embodiment of the invention, the method comprises: applying a compound of formula If χ represents bromine; D and B represent -CH=CH-; R16 represents hydrogen, hydroxy, or methyl 20 R1'' and R2'' represent a fluorenyl group, and 1117, 1118, 1117' and 尺 18' may be the same or different and represent hydrazine or fluorine, preferably hydrogen;

Rx and Rx' may be the same or different and represent hydrazine or fluoro, or rx together with rx' represent a single bond or a bridging group _〇_, optionally used with pharmaceutically acceptable excipients. 36 25 201023925 Within the process according to the invention, of particular importance are the following compounds of the formula If: cyanoic acid diphenylglycolate 曱 bromide; bis-propionic acid 2,2-diphenylpropionate methyl bromide Compound; 5 hydroxypropionic acid 9-hydroxy-α -9-carboxylate 曱 bromide; Cyclopropionic acid 9-methyl-hydrazine-9-carboxylate methyl bromide; Cyclopropionic acid 9-A Base-oxime-9-carboxylate methyl bromide; cyclopropionic acid 9-hydroxy-indole-9-carboxylate oxime bromide; φ cyclopropanoic acid methyl 4,4'-diphenyldicarboxylate Methyl bromide. The pharmaceutical composition according to the present invention may contain a compound of the formula If, optionally in the form of an individual optical isomer, a mixture of individual mirror image isomers, or a racemate thereof. Compounds of formula lg are known in the art (WO 03/064417). In another preferred embodiment of the invention, the method comprises: applying a compound of the formula lg, wherein \ _ / 10 A represents a double bond group selected from the group consisting of: ; _ represents chlorine, bromine, Or methanesulfonate, preferably bromine; R19 represents hydroxy or fluorenyl; 2〇R1"'and R2'" may be the same or different and represent a fluorenyl or ethyl group, preferably a fluorenyl group; R2Q, R21, R20' and R21' may be the same or different and represent hydrogen, -CF3, -CHF2, or fluoro, preferably hydrogen or fluoro, optionally used with pharmaceutically acceptable excipients. 37 201023925 In still another preferred embodiment of the invention, the method comprises: applying a compound of formula ig, wherein

A' represents a double bond group selected from the group consisting of: and X—representing bromine; 5 R19 represents a hydroxy group or a fluorenyl group, preferably a methyl group; R1”' and R2'" may be the same or different, representing A A base or an ethyl group, preferably a methyl group; the feet 3, 114, 113' and 114' may be the same or different and represent hydrogen or fluorine, optionally together with a pharmaceutically acceptable excipient. Of particular importance within the process of the present invention are the following compounds of the formula lg: tropinol 9-hydroxy-hydrazone-9-carboxylate methyl bromide; methylene alcohol 9-hydroxy-hydrazine-9-carboxylate hydrazine Bromide; tropinol 9-methylsan-9-carboxylate oxime bromide; isoxan 9-mercapto-purine-9-carboxylate oxime bromide; tropinol 9-ethyl -9 - carboxylate oxime bromide; tropinol 9-difluoroindolyl-n-n-9-carboxylate methyl bromide; sterol 9-hydroxyindenyl-indole-9-carboxylate methyl bromide. The pharmaceutical composition according to the invention may contain a compound of formula lg, 20 optionally in the form of individual optical isomers, mixtures of individual mirror image isomers, or racemates thereof, unless otherwise stated. Otherwise the alkyl groups used are branched and unbranched alkyl groups having from 1 to 5 carbon atoms. Examples of such are: mercapto, ethyl, propyl or butyl. fluorenyl, ethyl, propyl or Butyl selectivity 38 201023925 is abbreviated as Me, Et, Prop or Bu. Unless additional semester is used, the definition of propylene f and butyl also includes all isomeric forms that may be considered. Thus, for example, propyl includes N-propyl and isopropyl, and butyl includes isobutyl, secondary butyl, tert-butyl, etc. Unless the other acoustic ring saponin is an alicyclic hydrocarbon having three to six carbon atoms. It is particularly important in the context of the present invention to cyclate, cyclocyclyl, cyclosyl, and cyclohexene. According to the present invention, cyclopropane is particularly important within the scope of the present invention.

20 Unless otherwise stated, the alkenyl group used is a branched and unbranched double bond alkane bridge containing - five carbon atoms. Examples of such include: methylene, ethyl, propenyl or butenyl. Unless otherwise used, the branched and unbranched double bond alkane bridges containing one to four carbon atoms may be monosubstituted, disubstituted or disubstituted, preferably double substituted. Thus, unless specifically stated, the term olefin-0H represents a branched or branched double bond alkane bridge containing one to four carbon atoms which may be mono-, di- or tri-substituted, preferably mono-substituted. Unless otherwise stated, the alkoxy group used is a branched and unbranched alkyl group having one to five carbon atoms and linked by an oxygen atom. The following examples may be found above, for example: a methaneoxy group, an ethoxyoxy group, a propane fluorenyl group or a butane fluorenyl group. The decyloxy, ethoxyoxy, propaneoxy or butanoxy group can be optionally abbreviated to MeO, EtO, PropO or BuO. Unless otherwise stated, the definitions of propaneoxy and butanoxy include all possible isomeric forms. Thus, for example, the propenyloxy group includes a n-propyl aryl group and an isopropyl alkoxy group, and the butyl group includes an isobutoxyoxy group, a secondary butyloxy group, a tertiary butane group, and the like. The term Alkoxy (alkoxy) may also be used in place of the alkyloxy (alkoxy) group and is used within the scope of the invention. The decyloxy, ethoxyoxy, propanyloxy or butanoxy group may be optionally referred to as a decyloxy group, an ethoxy group, a propoxy group or a butoxy group. Unless otherwise stated, the alkenyl alkoxy group used is a branched and 5 10 15 20 unbranched double bond alkyl bridge containing from one to five carbon atoms, which may be alkoxy monosubstituted, disubstituted or trisubstituted Preferably, it is monosubstituted. Unless otherwise stated, the 〇_c〇_alkyl group used is a branched and unbranched alkyl group having one to four carbon atoms which is bonded by a monoester bond. The alkyl group can be bonded directly to the carbonyl carbon via an ester bond. The 〇 c〇-alkyl·halogen should be regarded as an analog thereof. Represents triacetate. One gas is not a special invention, and Fan is a fluorine, chlorine, desert or dish. In addition to - a few bases. Both abalone and desert are the preferred halogen elements. Co represents a view of the invention directed to a plurality of doses in a chamber. The Bedding collection consists of a multi-drug drug in February = another - view of the 'inhalation load'. In the multi-dose sachet package of the plurality of dosage forms in the package of the present invention, the inhalation is included in the package, and the inhalation of the capsule is preferred according to the present invention. Sleeping includes the compound of Chemical Formula 1, which is a substance. The following pharmaceutical contents are mixed to form a powder-mixed inhalable powder mixture. In order to prepare a disaccharide according to the invention (for example, lactose, sucrose, :: (for example, glucose or arabic), such as dextran ), sugar, trehalose), oligo-multiple enzymes (eg - (such as sorbitol, mannitol, xylose 25 201023925 alcohol), salts (such as sodium chloride, carbonated mixture. Sugar or bile - "good with other things" and particularly but not absolutely with its hydrates, the Portuguese J sugar is more than the purpose of the present invention 'lactose and lysine go to the second to achieve 5 10 15

20: The form is preferably a single form, and the shape of the object is a shape: its:: _ : t two ==: formula: two is the technique (for example, 'separating the mirror isomer by the color layer analysis work of riding the butterfly Both the racemate and the racemate. J wind or 'according to the hair _ inhalation device contains a terminal drug' which contains the active ingredient of the compound S3 except for the compound of the chemical formula 1. It is preferred that the additional active ingredient is P2 agonist 2, which is albuterol, bambuter, bitolterol, broxater〇1, cabbutero, carbuterol, clenbuterol (clenbuter〇1), fenoterol, fonntrop (fenn〇ter〇l), hexoprenaline, ibuterol, isoetharine, iso iSOprenaHne, levosalbutamol, mabuter〇l, meluadrine, metaproteren〇1, orciprenaline, Pibuterol, procaterol, reproterol, rimiterol, rittomon (ritodrine), salmeterol, 25 201023925 salmefemol, sterterenol, sulphonteiOl, tiaramide, special cloth Terbutaline, tolubuterol, CHF-1035, HOKU-81, KUL-1248, 3-(4-{6-[2-radio-2-(4-yl-3-) Methyl-phenyl)-ethylamino]-hexyloxybutyl benzenesulfonamide, 5_[2_(5,6-diethyl-hydroindol-2-ylamino)-1_yl-based-B Each of the radicals _ _ ketone, 4 hydroxy _7_[2_{[2_{[3_(2_phenylethoxy)propyl]sulfonyl}ethyl]-amino}ethyl] (3H)-benzoxanthone, 1_(2-fluoro, 4-phenyl)-2-[4-(1-benzimidazolyl)_2-methyl-2-butanyl]ethanol,口 普 methoxybenzyl-amino)-4-hydroxyphenyl]-2-[4-(l-benzimidazolyl)_2-methyl-2-butylamino]ethanol, ι_[2Η-5 -light-based 3-oxo-4H-1,4-benzopyrene _8_yl]-2-[3-(4-Ν,Ν·dimethylaminophenyl)_2_indolyl-2-propylamine Ethanol: 1-[2Η-5-hydroxy_3_oxy_4Η·Μ_benzopyrene _8_yl]_2_[3_(4_ 15 20 Ο methoxyphenyl)_2-mercaptopropylamine] Ethanol, 1-[2Η_5-transoxy 4Η 1,4-Benzene 0 _8_ base]_2 _[3_(4·n-butoxyphenyl)_2_methylIpropylamino]ethanol, via _3LM_benzopyrene _8_ base]; ^(4) is called 4-methoxyphenyl)- 1,2,4-triazol-3-yl]-2-mercapto-2_$amino}ethanol, 5-hydroxyl_8_(1 hydroxy-2-Isopropylaminobutyrene and octopus·3_(4Η) -ketone, amino_3_chloro-5_three I «a soil) 12-tert-butylamino)ethanol and 1-(4.ethoxycarbonylamino-3-ylindole) (Third butylamino)ethanol, optionally in the form of a mirror image isomer, a non-image isomer, and optionally a commercially acceptable acid addition salt and a hydrate thereof. It is stated that 'better β2 agonist 2 is selected from Bambutero, than '卞布特罗, Clenbuterol, Fenoterol, Formoterol, 42 25 201023925 Hessauline, different Dentero, 吼布特罗, Procaterol, Riptro, Shawutrol, salbutamol, natatar, terbutaline, tolutro, =(4-{6-[ 2-hydroxy-2-(4-carbyl-3-methyl-methyl-phenylethylamino)-hexyloxybutyl)-benzene hydrazide, 5, 5,6-diethyl _ gas _2_ Aminoamine 5 yl) hydrazino-ethyl]·8_ via hydrazino-quina, 4-carbyl-7-[2-{[2-{[3-(2-phenylethoxy)propyl Base] 醯 }}}ethyl]_amino) ethyl] 2 (called benzopyrene, noisy fluoro 4 phenyl) 2 benzophenidyl)-2-methyl-2-butyl Amino]ethanol small [3(4)methoxy+yl10-amino)-4_transphenylyl]_2_[4 servant and imidyl K-methyl 1 amine] ίο ethanol, 1-[211- 5-hydroxy-3-oxo-4H-1,4-benzopyrene _8_yl]_2_[3_(4_N,N-dimethylaminophenyl)_2-methyl·2_propylamino]ethanol, Η2Η_5_ According to the base _3|4η_μ_Benzyl yl] 2 cases of 4_ decyloxyphenyl)_2_f-yl-2-propylamino]ethanol, called 5--based _3_ oxy-4 Η-1,4- Stupid and $ -8-yl]-2-[3-(4-n-butoxyphenyl)_2-fluorenyl 15 _2-propylamino]ethanol, hydrazine 5 · thiol-3-oxo-4-indole-1,4- Benzo. No. 2, methoxyphenyl)-1,2,4-triazol-3-yl]_2-methyl-2_sodium butylamino}ethanol, 5-hydroxyhydroxy-2-isopropylamine Benzyl)-2Η-1,4-benzophenazine-3-(4Η)-_, ι_(4-amino-3_chloro-5-trifluoromethane basic)-2-second butyl Amino)ethanol and hydrazine-(4-ethoxylated 20-amino-3-cyano-5-fluorophenyl)_2•(t-butylamino)ethanol, optionally in the form of racemic , mirror image isomers, non-image isomers, and optionally pharmaceutically acceptable acid addition salts and hydrates thereof. More particularly, the p-mimetic agent (betamimetiCS) 2' employed in the composition according to the invention is selected from the group consisting of fenoterol, formoterol, sand 25 metro, 3_(4 gas 6-[2 -hydroxy-2-(4-hydroxy-3-hydroxymethyl-phenyl)_ 201023925 ethylamino]-hexyloxybutyl) sulfosulfonamide, 5_[2_(5,6-diethyl-fluorene Indole-2-ylamino)-1-hydroxy-ethyl]_8_hydroxy_1H_quino-2-_, 1-[3_(4-methoxy-yl-amino H. phenyl)-2-[ 4_(1_Standimidazolyl)_2·Methyl-2-butylamino]ethanol, W2H_5_hydroxy_3m4_Benzene-inhibited-8-yl]-2-[3-(4-N,N-II Amidinophenyl)·2_fluorenyl·2_propylamino]ethanol, 1-[2Η-5-hydroxy-3-oxo-4-indole-1,4-stupidyl tillage_8_yl]-2-[3 -(4-methoxyphenyl)_2-methyl-2-propylamino]ethanol, Η2Η-5-pyridyl-3-oxo-4-indole-1,4-benzoxan-8-yl]-2 -[3-(4.n-butoxyphenyl)-2-indolyl-2-propylamino]ethanol, and • hydroxy_3_ oxy-4H-1,4-benzo[$8_yl]_2_ {4_[3_(4_methoxyphenyl)1)2,4-diyl]-2-mercapto-2-butylamino}ethanol, optionally in the form of a racemate or a mirror image isomer Non-image isomer and optionally for music theory Acceptable acid addition salts and hydrates thereof. In the above-mentioned β51 and the β-mimetic agent, the compound formoterol, salmeterol, 3-(4·{6_[2-trans-base_2-(4-carbazyl-3-hydroxyindole·phenyl) )-ethylamino]-hexyloxy}-butyl)-phenylamine, and 5-[2-(5,6-diethyl-hydrogen-2-ylamino)-1-yl- Ethyl]-8-trans-yl-1Η-噎琳-2-_ is especially preferred, and may be selected in the form of a racemate, a mirror image isomer, a non-imaged isomer, and optionally It is a pharmaceutically acceptable acid addition salt and a hydrate thereof. According to an example of the present invention, the acid addition salt of the pharmacologically acceptable β-mimetic agent 2 is a pharmaceutically acceptable salt selected from the group consisting of hydrochloric acid, hydrogen desert acid, sulfuric acid, acid-breaking, methyl acid, Acetic acid, fumaric acid, glassy acid, lactic acid, citric acid, tartaric acid, 1-hydroxy 2-naphthoic acid, 4-phenyl cinnamic acid, 5-(2,4-difluorobenzene)salicylic acid or maleic acid . If otherwise anticipated, 44 25 201023925 a mixture of the above acids may also be used to prepare the salt 2. According to an embodiment of the present invention, the salt of the β-mimetic agent 2 is preferably selected from the group consisting of the following: a nitrite, a hydrobromide, a sulfate, a phosphate, a fumarate, a decyl sulfonate, a 4-phenyl cinnamate. Acid salt, 5-(2,4-difluorobenzene)salicylate, 5 maleate, and naphthalate (xinafoate). In the case of salmeterol, a particularly preferred salt 2 is selected from the group consisting of: chlorate, sulfate, 4-cinnamate, 5-(2,4-difluorobenzene) salicylate, especially naphthoic acid. Salt is especially important. In the case of formoterol, a particularly preferred salt 2 is selected from the group consisting of argon chlorate, φ sulphate and fumarate, with hydrogen hydride and fumarate being especially preferred. According to the invention, the most important one is formoterol fumarate. According to the present invention, the following salts are preferably used as the β-mimetic agent 2: salmeterol, formoterol, 3-(4-{6-[2-hydroxy-2-(4-hydroxy-3-)曱-yl-phenyl)-ethylamino]-hexyloxy}-butyl)-benzophenone, and 5-[2-(5,6-diethyl-murine-2-ylamine) Base-1-1-trans-yl-ethyl]-8-yl-l- 15-lH-quinolin-2-one. Of particular importance in accordance with the present invention are salmeterol salts and formoterol salts. The beta mimetic 2 also includes its opposite enantiomers © or a mixture thereof. In the pharmaceutical composition according to the present invention, the compound 2 may be present in the form of a racemate, a mirror image isomer, or a mixture thereof. Both the mirror image isomer and the racemate can be successfully separated using techniques well known in the art (e.g., by color layer analysis for palm phase change 20, etc.). If the form of the compound 2 used is its mirror image isomer, it is especially preferred to be able to use a mirror image isomer having a C-OH group having an R structure. Alternatively, the inhalation device according to the present invention contains a plurality of doses of the medicament in the form of a powder containing, in addition to the compound of Chemical Formula 1, a steroid 3 as another active ingredient. 45 201023925 In such a combination of agents, steroid 3 is preferably selected from the group consisting of: prednisolone, prednis〇ne, butixocortpropionate ^ RPR-106541, flunisin Flunisolide, spirulina, triaincin〇l〇ne, budesonide, fluticasone, mometasone, ciclesonide, roflucylide, ST-126, dexamethasone, (s) fluoroyl sulfonyl 6α, 9α_difluoro-17α-[(2_ bromocarbonyl)oxy]_11β_ thiol_16 (χ•methyl_3_oxy_xiong-1,4- Di-salt-β7-methylthiosulfate, (8)_(2_oxy-tetrahydro-trinium_3S_ 10 15 20 base) 6α,9α-difluoro_up_hydroxy_16α_methyl_3_oxy_17 〇1 propyl decyloxy-androst d,4-diene-Πβ-indole thiosulfate, and etipredn〇1 di-acetic acid acetate (BNP_166), optionally in the form of a racemate , mirror image isomer, non-image isomer, and may be selected in the form of its salts and its derivatives 'solvates and / or hydrates. In a particularly preferred combination of agents, the steroid 3 is preferably selected from Including condensed ', chlorhexidine, Qu Anxilong Budesonide, Fluticasone, F-Misson, Cyclosporine, Rofluonide, ST-126, Dimethasone, (s) _ Soil 6α, 9α-Fluoro-ΐ7α·[(2-0 Alkyl oxy ηβ_ carbyl group: oxy-andro-1,4-diene-17β-methylthiosulfate, (8) _(2_ ❹ , tetrahydrofuran-3S-yl) 6α, 9α -difluoro-11β-radio- 16α_methyl_3_ and ipprodyloxy-androst-1,4-dienethiosulfate, as the isomer dichloroacetate, may be selected The form is a racemate, a mirror image and its enrichment of a non-image isomer, and may be selected in the form of a salt thereof, a hydrazine, a solvate thereof and/or a hydrate. In a preferred combination of agents, Steroid 3 is selected from budesonide " tube cedar, mometasone, ciclesonide, (S)-fluoromethyl 6α, 9α_difluoro 46 25 201023925 -17α-[(2-bityl) Oxyl; μ1β_ via _16α_methyl_3_oxy-androstene-17β-methylthiosulfate, (8) _(2_oxy_tetrahydro-furan-38-yl) 6〇 (, 9〇1 _Difluoro-11β·transyl-16α-methyl-3-oxo-17α-propanyloxy-andro-1,4-diene-Ι7β-methylthiosulfate, and Epson-dichloroacetic acid salt, Select 5 in the form of racemic rotation thereof, enantiomers, diastereomers, and optionally in the form of their salts, and derivatives thereof 'solvates and / or hydrates. Correlation with steroid 3 includes any salts or derivatives, hydrates or solvates that may be present. Examples of possible salts and quinones of steroids 3 are gold-requiring salts, such as sodium salts or salt-removing salts, phenylbenzene 10 sulfonium salts, decanoates, isonicotinates, acetates. , propionate, dihydrogen phosphate, palmitate, pivalate, or thiolate (furcate). Alternatively, the inhalation device according to the present invention contains a plurality of doses of the powder form of the medicament, in addition to a compound of the formula formula, which additionally contains 15 other compounds, one of which is the above-mentioned ρ simulant 2, and the other One is the steroid 3 mentioned above. Thus, in a preferred embodiment, the present invention is directed to an inhalation device comprising: an outer casing and a sachet strip, the strip being movable and sequentially aligned with the sachets for opening a member of the sachet, such that the user (4) is inhaled, and the i-rotating member is capable of catching and winding the strip, wherein each sachet contains a pharmaceutical ingredient in powder form, and the medicament therein The composition includes at least one compound of the formula ,, preferably a compound. In another embodiment, the present invention relates to an inhalation device, a package comprising a housing and a sachet strip, the miscellaneous strip moving to sequentially cause the members of each 201023925 capsule to enable the user to suck The housing includes a chamber for receiving a strip of the sachet and a loop formed by the opened pouch in the strip, the configuration of the chamber being made with the opening of the pouch The loop formed by the opened sachet occupies the space occupied by the strip originally in the chamber, and the pouch contains the pharmaceutical ingredient in powder form, and the pharmaceutical ingredient thereof includes at least one of the chemical formula 1. The compound is preferably a compound. In the range of the inhalable powder according to the present invention, the adjuvant has a maximum average particle size of not more than 250 μm, preferably between 1 Å and 150 μm, more preferably between 8 Å and 〇. Sometimes, 15 20 ❹ 亦 is also suitable for adding slightly finer adjuvants with an average particle size of ΐμιη to 9 μm. This purely detailed lion can be selected from the available adjuvants listed above. Finally, in order to prepare the inhalable powder according to the present invention, an extremely fine active substance 丨 can be produced, or 2 and/or 3 active materials can be selected, and the preferred average particle size is 〇·5 μιη to; Ηηι, more preferably from Ιμιη to 6μιη, is added to the adjuvant mixture. It is well known in the art to manufacture the inhalable powder according to the present invention by milling and micronizing it, and finally mixing all of the ingredients. For a method of preparing a pharmaceutical ingredient in powder form, reference is made to WO 02/30390, WO 03/017970, or the disclosure of the inner valley as disclosed in WO 03/017979. The contents of WO 02/30390, WO 03/017970, and WO 03/017979 are incorporated herein by reference. The pharmaceutical composition according to the present invention can be obtained by the method described below, and is merely exemplary. 48 25 201023925. The first and the active substance are placed in a suitable mixing container. Preferably, the average particle size of the animal (4) is from g·5 to 10, to _, more preferably 2 μη to 5 μηη. Adjuvant and active ruler = addition process preferably uses 1 mesh or - granulated mesh, the mesh size is (Umm to 2 ugly, preferably 〇3 to imm, more preferably = to 0.6 ugly. Jiadi will first add the main container to the Zuo (4) people. The special money surface is first screened in alternating layers. When the two ingredients are added during the addition process, the adjuvant and the active substance will be screened. After the completion of the mixed component-layer-layer family and the completion of the chemical preparation procedure, if the active crystal form selected in the above process still does not reach the above particle size, the instrument can be combined with the above-mentioned standard. The particle size (this procedure is also known as micro 15 ❿ 20 in the text (4) Lai" special _, the industry (10) the practitioner knows many improvements and variations of the invention, and the above description should only be preferred In addition, in the above description, the hole formed on the wall surface enables the capsule strip to be taken from the unused portion of the I (4) portion, and the packet is cut into the end of the money surface and the inhaler housing. a hole between the hole and the hole formed in the wall and away from the distal end, and these changes are covered Scope of the invention and the scope of the patent. Brief description of the stomach pattern] Figure la and lb are side cross-sectional views of the conventional suction device, shown by 49 25 201023925 - the actuator is moved from the position in Figure la to When the map-index wheel is used, the two positions in a belt drive a sac to pass through the sac. When the actuator returns to the figure as shown in the figure, a puncturing head positioned on the actuator will align the alignment. At the time, FIG. 2 is a cross-sectional view of the inhalation device, the scented annular ring; and the type of the read strip is wound around itself. FIGS. 3a and 3b show the frontal section of the previously disclosed annular ring. Figure and back section view, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , The sac strip and the - coiled component = 15 20 used part, the chamber is not used - ^ ^ in the eve (1) v η and the spiral disk is separated by a flexible partition - both a shape capsule chamber and a used capsule chamber; ❹ Figure 5 shows the portion of the transverse shell Section \ Figure 'How the green elastic partition wall is compressed and held between the side walls of the outer casing; = to 6: shows a series of patterns: the edge is used when the spiral coiled element is filled with the portion of the funnel Figure 7a and 7b show a modified version of the illustrated suction device, and wherein the resilient dividing wall surrounds the outer surface of the helically wound element and is at least partially attached thereto. In 7a, all the sachets have not been used, so the spirally wound element is empty. However, in the figure %, all the capsules of 50 25 201023925 are used and the spirally wound element and the elastic partition wall are maximized. Degree; θ 5 10 15

20 shows an embodiment of the inhalation device of the present invention, which is similar to FIG. 4, but includes a member for avoiding passage of residual powder through the passage between the used capsule chamber and the unused capsule chamber. From a used /, sac room into the unused sac chamber, which channel is intended to be 4S said old.

Figure 9 is a plan view showing the area in the circle L of Figure 8 as seen from above; Figure 10 shows another embodiment of the inhalation device similar to Figure 8; Figure 11 shows the area in the circle of Figure 1 from above. Figure 2A to 12C show another structure of the flexible assembly of the embodiment of Figures 10 and 11; Figure 13 shows another embodiment similar to the inhalation device of Figures 8 and 10; Figure 14 is a partial cross-sectional plan view of the region of the circle of Figure 12 as seen from above; Figure 15A to Figure 15C show another structure of the flexible assembly of the embodiment of Figures 10 and 13; Figure 16 shows and 8. Another embodiment similar to the inhalation device of Figures 10 and 13; and Figure 17 shows a partial cross-sectional plan view of the region within the circle of Figure 16 as viewed from above. [Main component symbol description] 51 25 201023925 1 Inhaler 2, 25, 7 271 Housing 2a, 2b Side wall surface 3a Pouch 4, 274 Indexing mechanism 5, 13 , 275 Actuator 6, 276 Pouch holder 0 7 ,277 capsular puncture site 8 剌 剌 element 9,279 mouth 10 , 70 , 270 inhalation device n , 12 , 24 central reel 3 , 14 , 21 band 15 , 90 , 91 , 290 partition wall 20 ring type Device 21 strip segment 22 loop 23 gear 60, 260 spiral coiled element 52 201023925

61 Capsule strip 61a » 261a Unused part 71a Vertical rib rib 90, 91 partition wall 290a, 290b, 290a', 290a," end 291 rib 292 passage 293 first element 294 second element 295 Arched vacancy 296a rectangular slit 296b semicircular portion 297 hole 53

Claims (1)

201023925 VII. Patent application scope: 1. An inhaler comprising an outer casing for accommodating a strip containing a plurality of sachets, each sachet containing a dose of medicament, the outer casing comprising a first compartment 5 for accommodating a used sachet, and a second compartment for containing the used sachet, the first compartment and the second compartment being separated by a flexible or movable partition; a member for Each of the sachets is sequentially moved to be aligned with a member for opening a sachet to allow the user to inhale the dose; and a spirally wound member for winding the strip 10, wherein the inhaler is included A passage between the first compartment and the second compartment, and a blocking member located in the conduit to prevent the powdered medicament from entering the first sachet compartment from the second sachet compartment via the passage. [2] The inhaler of claim 1, wherein the spirally wound element is configured such that a plurality of strips formed by a sachet that is aligned with the member for opening a sachet are The used portion is gradually wound into the spiral wound component. The inhaler of claim 1 or 2, wherein the spirally wound element is rigid. 4. The inhaler of claim 1 or 2, wherein the spiral wound element is formed from a flexible material. The inhaler of claim 4, wherein the spiral wound element is formed of a deformable and inelastic material. 6. The inhaler of claim 5, wherein the spiral disk 5 is formed of a resilient deformable material around the component. 7. The inhaler of claim 6, wherein the selection of the elasticity of the helically wound element is dependent on the stiffness of a strip of the capsule to create any substantial deformation or expansion in the helically wound element. Ίο Previously, one of the sac strips had been used to form a first seal ring in the spiral wound element. 8. The inhaler of any one of claims 4 to 7 wherein the helically wound element is configured such that the portion 15 of the sachet strip is wound around the helically wound element As the length of the inner length increases, the spirally wound element expands accordingly. The inhaler of any one of the preceding claims, wherein the spiral wound element has at least one coil system exceeding 360°. The inhaler of any one of the preceding claims, wherein the stiffness of the helically wound element varies along at least a portion of its length. The inhaler according to claim 10, wherein the spiral 55 201023925 coiled component emits a phase-brain core, and the inner end is away from the outer end, and the rigidity of the spiral coiled element faces the inner end Decrease at least in part. 5 a. The inhaler of claim 1, wherein the thickness of the spiral wound element decreases toward the inner end. The inhaler of the invention of claim 12 or 12, wherein the spiral The inhaler of the coiled 7C member is tapered toward the inner end. The inhaler of claim 5, wherein a plurality of holes are formed adjacent to the inner end of the spiral wound member. An inhaler according to any one of the preceding claims, wherein the material for forming the spiral wound element is filled with bronze, stainless steel, 'dragon, acetal or polypropylene. The inhaler of the present invention, wherein the spiral wound element is a coil spring. The inhaler of any one of the preceding claims, wherein the shape of the beta-resistance member conforms to the strip of the capsule. The inhaler of claim 17, wherein the barrier member comprises a flexible component to form a seal of the sachet strip. 56 201023925 19. As described in claim 18 Inhaler, The barrier member is configured to align one of the sachets of the sachet strip, and the other sachet is aligned with the member for opening a sachet. 5 20. Any of the foregoing patent claims The inhaler includes means for first crushing and/or tearing the opened drug capsule before the opened drug bag enters the spiral wound element. /-) 1 ίο 21 · An inhaler The utility model comprises a casing for accommodating a strip containing a plurality of sachets, each sachet containing a dose of the medicament; and a member for sequentially moving the sachets to be aligned with a member for opening a sachet To enable the user to inhale the dose, the inhaler has a first compartment to accommodate the unused sachet, and a second compartment to accommodate the used pouch, the first compartment and the second compartment The compartments are separated by a flexible or movable dividing wall, the partitioning wall including a hole for the sachet strip to enter the second compartment from the first compartment, the aperture being included to avoid The powder enters the unused sachet from the used sachet compartment through the hole An intervening member, wherein the inhaler is used to prevent the powder from passing through the 20 member, and is shaped to conform to the shape of the sachet strip. 22. 25 The inhaler according to claim 21, Where the means for preventing passage of the powder comprises a flexible component to form a seal against the bag strip. 25 57 201023925 23. An inhaler comprising a housing for receiving a strip containing a plurality of sachets The bag, each of the sachets containing a dose of the medicament, and a member for sequentially moving the sachets to align with a member for opening a sachet, such that a user can inhale the dose, The inhaler has a first compartment to accommodate an unused sachet, and a second compartment to accommodate the used sachet, the first compartment and the second compartment being flexible or The moving partition wall is spaced apart, the partition wall includes a hole for the bag strip to enter the second compartment from the first compartment, the hole pocket is included to prevent the powder from being used. The sachet compartment is detached from the unused hole through the hole Balloon member compartment, wherein the means to avoid the escaping powder comprises a flexible assembly for generating a sealing strip of the drug capsule. The inhaler of claim 22, wherein the flexible component is shaped to conform to the shape of the sachet strip. 25. The inhaler of claim 24, wherein the flexible component is integrally formed with the dividing wall. The inhaler of any one of claims 21 to 25, wherein the member for preventing the powder from escaping is disposed to align one of the sachets of the sachet strip, at this time A sachet is aligned with the member for opening a sachet. The inhaler of any one of clauses 21 to 26, wherein the member comprises a brush or elastic member extending over at least partially over the hole in the partition wall . The inhaler of any one of claims 1 to 20, wherein the outer casing includes a common chamber to accommodate unused and used portions of the sachet strip. 29. φ w 10 The inhaler of claim 28, wherein the chamber is configured such that when the size of the used portion of the strip is increased, the strip has been used in the strip A portion of the chamber will occupy an area of the chamber that is initially occupied by unused portions of the sachet strip. The inhaler of claim 29, wherein the shared chamber is divided into an unused sachet compartment and a used sachet by a flexible and/or movable partition wall. Compartment. The inhaler of claim 30, wherein the partition 20 is rigid but configured to slide within the outer casing such that the unused and the relative of the used sachet compartment The inhaler according to claim 30, wherein the flexible and/or movable partition wall is fixed to the outer casing 25 59 201023925 with one or both ends thereof. 33. The inhaler of claim 30, wherein the partition wall is moveable and secured to the outer casing at one end, the crucible being pivotable about the end within the outer casing. The inhaler of claim 30, wherein the partition wall is flexible and extends across a space between opposing side wall surfaces of the inhaler to prevent the powder from being used and used. The medicine 10 passes between the capsule compartments. The inhaler of claim 34, wherein the elastic partition wall extends between the side wall surfaces by a width greater than a distance between the side wall surfaces, such that the flexible partition wall is compressed and held on the side wall surface. 15 rooms. 36. The inhaler of claim 33, wherein the flexible dividing wall comprises a foam strip. The inhaler of claim 36, wherein the blister strip comprises a stiffening element. The inhaler of any one of claims 30 to 37, wherein the flexible partition wall is at least partially attached to the spiral coiled 25 element. The inhaler of any one of claims 22 to 27, comprising a member for squeezing, slitting and/or tearing the used portion of the bag strip. The inhaler of any one of claims 1 to 20, comprising a second helically wound element, the unused sachet strip being wound within the second helically wound element and When assembled, it is located within the housing such that during use of the inhaler, when the first coiled element is expanded, the second helical coiled element contracts because of the portion of the strip that is used As the size of the loop increases, the size of the loop formed by the unused portion of the strip is reduced. The inhalation device of any one of claims 1 to 20, wherein the housing comprises a common chamber for accommodating an unused sachet strip and the sachet strip In the used portion, a flexible and/or movable dividing wall separates the chamber into a used and unused sachet compartment. The inhaler of claim 41, wherein the flexible partition wall is fixed to the outer casing with both ends thereof. 43. The inhaler of claim 41, wherein the dividing wall is flexible and configured to extend across a space between the wall faces of the side 25 of the inhaler to prevent powder from being in the Crossed between used and used 61 201023925 sachet compartments. 44. The inhaler of claim 43, wherein the width of the flexible dividing wall is greater than the distance between the side wall faces such that the flexible dividing wall is compressed and held between the side wall faces. The inhaler of any one of claims 41 to 44, wherein the flexible partition wall comprises a blister strip. The inhaler of claim 45, wherein the blister strip comprises a stiffening element. The inhaler of any one of claims 41 to 46, comprising a second spiral wound element for accommodating an unused 15 bag strip for insertion into the housing during assembly The structure is such that when the size of the loop formed by the used portion of the strip is increased and the size of the loop formed by the unused portion of the strip is reduced, the first spiral coiled component is expanded. The second helical coiled element contracts. The inhaler of any one of claims 1 to 4, wherein the spirally wound element is configured such that a front end of a used portion of the sachet strip begins When the spiral wound component is contacted, the spiral coiled component is unfolded, and the portion of the strip that has been used 25 has not yet undergone any deformation due to the helical coiled component. 49. The inhaler of claim 48, wherein the helical coiled element is configured to be partially unfolded or rolled apart across an inner wall forming part of the outer casing. 50. The inhaler of claim 48 or claim 49, comprising a member for stabilizing the helically wound element to increase the length of the used portion of the strip contained within the helically wound element When, avoid ® ίο to avoid excessive expansion. 51. The inhaler of claim 50, wherein the member is the flexible dividing wall, separating the shared chamber into unused and used sachet compartments. The inhaler of claim 51, wherein the flexible dividing wall is at least partially attached to the spiral wound element. The inhaler according to any one of the preceding claims, wherein the spiral coiled element is configured such that when filled in the sachet strip When used, the diameter is increased by at least 3 times relative to when the spiral wound element is empty. The inhaler of any one of the preceding claims, wherein 63 201023925 the outer casing houses a loop strip comprising a plurality of sachets. 55. The inhaler of claim 54, wherein at least a portion of the loop strip containing the sachet has passed through a member for opening a sachet to form a used portion. The used portion of the strip is wound within the spiral wound element. 64